GlassScriptPhysician profile
Adam Jarrett Lyons
NPI 1679950562
$1,907.35
in general payments reported to CMS, 2019-2025
32 companies · $260 in 2025
The $260 reported for 2025 was more than what 75% of Sports Medicine (Internal Medicine) providers received nationally (typical 2025 total: $99.49).
See the full distribution for Sports Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.13 · 2020: $269 · 2021: $231 · 2022: $445 · 2023: $324 · 2024: $339 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.61 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.67 | 2021-2025 | Trintellix |
| Gilead Sciences, INC. | $142.26 | 2020-2023 | |
| Incyte Corporation | $138.07 | 2021-2023 | Opzelura |
| Neos Therapeutics, LP | $114.29 | 2019-2023 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $81.66 | 2024-2025 | |
| Novo Nordisk INC | $71.90 | 2020-2021 | |
| Daiichi Sankyo INC. | $67.56 | 2020 | |
| Viiv Healthcare Company | $58.14 | 2022-2025 | Apretude |
| Vertos Medical, INC. | $48.36 | 2022 | |
| Hologic Sales and Service, LLC | $45.93 | 2020-2024 | Aptima |
| Abbott Laboratories | $45.16 | 2023 | Proclaim |
| Glaxosmithkline, LLC. | $40.38 | 2021-2023 | Shingrix, Arexvy |
| Kaleo, INC. | $38.46 | 2020-2022 | |
| Tris Pharma INC | $37.49 | 2022-2023 | Dyanavel Xr |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.65 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.53 | 2025 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.32 | 2019-2020 | |
| Grifols USA, LLC | $28.04 | 2024 | Xembify |
| Alexion Pharmaceuticals, INC. | $26.88 | 2024 | Soliris |
| Agile Therapeutics, INC. | $24.76 | 2021 | |
| Pfizer INC. | $24.57 | 2025 | |
| Adlon Therapeutics L.P. | $20.94 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.45 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.44 | 2024 | Dysport |
| Theratechnologies INC. | $18.51 | 2024 | Trogarzo, Egrifta |
| Amarin Pharma, INC. | $17.71 | 2022 | |
| Depuy Synthes Sales INC. | $17.27 | 2020 | |
| Merck Sharp & Dohme LLC | $16.94 | 2025 | Capvaxive |
| Idorsia Pharmaceuticals US INC | $16.45 | 2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $15.62 | 2023 | Qelbree |
| Lundbeck LLC | $14.33 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.